170 related articles for article (PubMed ID: 16960153)
21. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
[TBL] [Abstract][Full Text] [Related]
22. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
23. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
[TBL] [Abstract][Full Text] [Related]
24. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
25. Iron chelation.
Chandy M
J Assoc Physicians India; 1991 Sep; 39(9):665-6. PubMed ID: 1814896
[No Abstract] [Full Text] [Related]
26. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
[TBL] [Abstract][Full Text] [Related]
27. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
[TBL] [Abstract][Full Text] [Related]
28. Combined therapy with deferoxamine and deferiprone.
Kattamis A
Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
[TBL] [Abstract][Full Text] [Related]
29. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Kontoghiorghes GJ; Kolnagou A
Lancet; 2003 Jan; 361(9352):184. PubMed ID: 12531621
[No Abstract] [Full Text] [Related]
30. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
Kontoghiorghes GJ
Expert Opin Emerg Drugs; 2006 Mar; 11(1):1-5. PubMed ID: 16503822
[TBL] [Abstract][Full Text] [Related]
31. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
32. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
[TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapy of iron overload in thalassaemic patients.
Ceci A; Felisi M; De Sanctis V; De Mattia D
Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
[TBL] [Abstract][Full Text] [Related]
34. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
[TBL] [Abstract][Full Text] [Related]
35. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
36. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
[TBL] [Abstract][Full Text] [Related]
37. Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Fernandes JL
Transfusion; 2012 Oct; 52(10):2256-68. PubMed ID: 22404719
[TBL] [Abstract][Full Text] [Related]
38. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
Peng CT; Tsai CH; Wu KH
Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
[TBL] [Abstract][Full Text] [Related]
39. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
[TBL] [Abstract][Full Text] [Related]
40. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
St Pierre TG
Lancet; 2003 Jan; 361(9352):182; author reply 183-4. PubMed ID: 12531617
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
